• Institution: LOCKSS
LOCKSS

Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

Figure 8
Figure 8

Stratification of 35 SLE patients into groups expressing low ((a) green), moderate ((b) gray), and high ((c) red) IFN-α/β-inducible gene signaturebased onmedian fold change across the 21-gene panel of IFN-α/β-inducible genes. Kernel density estimates (i.e., histograms or frequency plots) for each SLE individual are calculated and graphed using the fold change foreach of the 21 genes from each SLE patient on the Formula scale to provide a representation of the distribution of 21 gene fold change values. The vertical dashed lines partition the 3 classes of IFN-α/β-inducible gene signature scores: 7 individuals with a weak IFN-α/β-inducible gene signature = median fold change <1.91 (0.93 on Formula scale); 8 individuals with a moderate IFN-α/β-inducible gene signature = median fold change between 1.91 and 5.53; and 20 individuals with a strong IFN-α/β-inducible gene signature = median fold change >5.53 (2.47 on Formula scale). IFN = interferon; SLE = systemic lupus erythematosus.

This Article

  1. Hum Genomics Proteomics vol. 1 no. 1